Galena Biopharma, Inc. Message Board
-
Ponder on this.
Herceptin's revenue worldwide in 2011 is 6 billion and it only targets about 20% of breast cancer patient population. GALE's Neuvax is targeting about 50-60% of breast cancer patient population. With a fully diluted share count of 125 million and potentially 3 times more earnings than Herceptin, we are looking at around $140 per share. And that is for the breast cancer indication alone. Even just a third of that, you are looking at a potential 20 bagger here. Why this is still trading below 2 bucks is beyond me. .
Sentiment: Strong Buy
-
This is how I came to my price of 148pps. IF this drug brings in approx. 5 billion a year (Herceptin brings in 6 billion and NeuVax will help a greater %) Lets say they do a 50/50 partnership so that brings in 2.5 billion/year. A conservative 4X earnings = 10 billion market cap. This would be about 81X greater than the current market cap of 122.4 million. That would bring the share price to about $148. I realize that this doesnt take into some dilution in the future. Please feel free to correct me if I am missing something here.
Sentiment: Strong Buy
- 2 Replies to nostradomus33
-
Have you ever seen a company go that high before, when it is such a low price now? Thanks
Sentiment: Hold
-
i believe neuvax is a lot cheaper than herceptin.
Sentiment: Buy
-
Bashers, pay-masters and shorts are deliberately pulling Gale share price down.
-
Love this, it really SMACKS a good one on the shins of the detractors!
-
Keep up the good logic flow.... who knows, your numbers may prove accurate???
-
gale
-
gale
-
certainly worth Pondering...
-
Wow! Interesting information. Invest $17,000 for the opportunity for $250k!! I like the risky reward opportunity here! Based on what I've read, this is a very likely scenario that could play out in the next year! All IMO.
Sentiment: Strong Buy
- 2 Replies to prospern23
-
Let's keep this UP for a while....
-
good points to ponder
-
I also come up with a pps of over $100 if these early esimates of sales are correct (dont see why they wouldnt be) along with a 50/50 partnership. Best risk/reward in bio today.
Sentiment: Strong Buy
-